Prostate Cancer Cases Rising 3% Yearly, Early Detection May Help

The American Cancer Society (ACS) predicts a rise in prostate cancer cases, with 333,830 new cases expected in 2026. Between 2014 and 2022, the number of cases increased by around 3% each year, with a significant surge in advanced-stage diagnoses. The ACS attributes this increase to more men being screened, though many still fail to undergo early screenings.

Dr. William Dahut, the ACS's chief scientific officer, highlights that both more diagnoses and a growing share of advanced-stage cases indicate that screening conversations occur too late for too many men, especially those at high risk. Prostate cancer screening, particularly during Prostate Cancer Awareness Month, is crucial in detecting the disease at an earlier stage, enhancing treatment options and survival rates.

According to the ACS, 1 in 8 men will receive a prostate cancer diagnosis in their lifetime. However, most diagnosed men do not die from the disease. In fact, more than 3.5 million men in the U.S. have survived prostate cancer.

Early detection is key, with localized prostate cancer having nearly a 100% 5-year survival rate. Treatment options are more expansive and less aggressive when cancer is detected early, maintaining better quality of life by minimizing impacts on urinary function and sexual health. Risk factors such as age, race, obesity, family history, and genetics also play significant roles in prostate cancer development.

The ACS recommends discussing prostate cancer screening with a healthcare professional starting at age 50 for those with average risk, 45 for those with high risk, and 40 for those at even higher risk.